Printer Friendly

Research and Markets: Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline Review, H2 2012.

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/593pbs/lebers) has announced the addition of Global Markets Direct's new report "Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline Review, H2 2012" to their offering.

Global Markets Direct's, 'Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy), complete with latest updates, and special features on late-stage and discontinued projects.

It also reviews key players involved in the therapeutic development for Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy). Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

- A snapshot of the global therapeutic scenario for Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy).

- A review of the Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

- Coverage of products based on various stages of development ranging from discovery till registration stages.

- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

- Coverage of the Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) pipeline on the basis of route of administration and molecule type.

- Key discontinued pipeline projects.

- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy).

- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.

- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

For more information visit http://www.researchandmarkets.com/research/593pbs/lebers

Source: Global Markets Direct
COPYRIGHT 2013 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Feb 5, 2013
Words:444
Previous Article:Research and Markets: Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Review, H2 2012.
Next Article:Research and Markets: LTE Pricing Strategies for Consumer Handsets: Case Studies of NTT DOCOMO and Verizon Wireless.
Topics:

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters